SCHEMBL1543057

SCHEMBL1543057

COc1c(C(=O)c2ccc(O)cc2)cc(-c2ccc[nH]c2=O)cc1C(C)(C)C

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 4/20 0.48
ALDH1A1 P00352 4/20 0.36
LMNA P02545 4/20 0.36
MAPT P10636 2/20 0.36
HPGD P15428 2/20 0.36
MAPK1 P28482 2/20 0.36
KDM4E B2RXH2 1/20 0.36
RECQL P46063 1/20 0.36
HSD17B10 Q99714 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.35
GAA P10253 1/20 0.34
TNFRSF1A P19438 1/20 0.34
KMT2A Q03164 3/20 0.34
MEN1 O00255 2/20 0.34
ABL1 P00519 2/20 0.34
NPC1 O15118 1/20 0.34
POLB P06746 1/20 0.34
RAB9A P51151 1/20 0.34
TUBB4A P04350 4/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1542980 0.91 CYP3A4 (0.49) CYP3A4ALDH1A1LMNAMAPTHPGD
SCHEMBL1543014 0.91 CYP3A4 (0.47) CYP3A4ALDH1A1LMNAKDM4EL3MBTL1
SCHEMBL1543192 0.90 CYP3A4 (0.47) CYP3A4LMNAABL1NPC1POLB
SCHEMBL1543061 0.88 CYP3A4 (0.51) CYP3A4ALDH1A1LMNAL3MBTL1GAA
SCHEMBL1543290 0.86 CYP3A4 (0.47) CYP3A4TNFRSF1AABL1TUBB4ATUBB
SCHEMBL1542920 0.85 CYP3A4 (0.46) CYP3A4ABL1TUBB4ATUBBTUBA3C
SCHEMBL1542836 0.85 CYP3A4 (0.46) CYP3A4LMNANPC1POLBTUBB4A
SCHEMBL1542633 0.85 CYP3A4 (0.46) CYP3A4ALDH1A1LMNAKDM4EKMT2A
SCHEMBL2128919 0.83 CYP3A4 (0.52) CYP3A4L3MBTL1TNFRSF1AABL1
SCHEMBL1542483 0.82 CYP3A4 (0.44) CYP3A4TUBB4ATUBBTUBA3CTUBA1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8273773-B2 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC (US) 2012-09-25 US claimed
EP-2307372-B1 HETEROCYCLIC ANTIVIRAL COMPOUNDS HOFFMANN LA ROCHE (CH) 2012-04-25 EP claimed
EP-2307372-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS F. Hoffmann-La Roche AG (CH) 2011-04-13 EP claimed
WO-2010010017-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2010-01-28 WO claimed
US-20100021423-A1 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC 2010-01-28 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100021423-A1 Heterocyclic antiviral compounds POLR2A, RRM2B, RRP1B CYP3A4 528/4885ALDH1A1 1136/4885LMNA 2389/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.